Fig. 2.
In vivo treatment with α-GalCer prevents EAE. (A) The 2D2 transfer model uses traceable MOG-specific naïve CD4+ T cells purified from CD45.1 congenic 2D2 mice. Twenty-four hours after transfer of 105 CD62L+CD25− CD4+ T cells, the recipient CD45.2 C57BL/6 mice were immunized with MOG35–55 in the presence either of α-GalCer or the PBS/DMSO solvent (vehicle). (B) The average clinical score from α-GalCer-treated mice (open circles, n = 8) and vehicle-treated controls (filled circles, n = 7) from 2 independent experiments is presented.